FMP
Millendo Therapeutics, Inc.
MLND
NASDAQ
Inactive Equity
Millendo Therapeutics, Inc., a late-stage biopharmaceutical company, focuses on developing novel treatments for orphan endocrine diseases in the United States. Its lead product candidates include livoletide, a potential treatment for Prader-Willi syndrome; nevanimibe, a potential treatment for patients with classic congenital adrenal hyperplasia; and MLE-301, a neurokinin 3-receptor antagonist for the treatment of vasomotor symptoms in menopausal women. The company is headquartered in Ann Arbor, Michigan.
1.06 USD
-0.06000006 (-5.66%)
Retained Earning Schedule
Year
2020
2019
2018
2017
Retained Earnings (Previous Year)
-208.65M
-164.09M
-301.48M
-250.18M
Net Income
-36.41M
-44.57M
-27.19M
-50.98M
Stock Repurchases
0
0
0
0
Dividend Paid
0
0
0
0
Retained Earnings
-245.06M
-208.65M
-164.09M
-301.48M
Other Distributions
-36.41M
-44.57M
137.39M
-51.3M
All figures are in USD.
